RNPC1 was found to be expressed in bladder, blood, brain, breast, colorectal, eye, head and neck, lung, ovarian, skin and soft tissue cancer. In 14 of the 94 tests, an association between RNPC1 gene expression and cancer prognosis was observed.

Investigated RNA-binding region-containing protein 1 (RNPC1) action on signal pathways and disease progression in lung cancer samples and cells. Found RNPC1 acts to downregulate the miR-181a mediated inhibition of cancer susceptibility 2 (CASC2) expression in lung cancer. Results show RNPC1 inhibits NSCLC progression in a miR-181a/CASC2 axis-dependent manner.

Cumulatively, these results reveal a novel mechanism of RBM38-mediated regulation of the HIF1A/miR-34a/SIRT1/p53 axis under hypoxia in non-small cell lung cancer cells.